Stockscreener 앱 받기
11.84
0.75%
-0.09
Omeros Corp 주식(OMER)의 최신 뉴스
H.C. Wainwright reiterates Omeros stock rating on rival trial miss By Investing.com - Investing.com Canada
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros Corp (OMER) Institutional Confidence - TradingKey
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty - GuruFocus
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights - Stocktwits
OMER | Omeros Corporation FinancialsIncome Statement - Quiver Quantitative
Omeros Corp (OMER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Omeros Corp (OMER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Omeros Corporation For: 24 July By Investing.com - Investing.com South Africa
OMER|Omeros Corp|Price:11.340|Chg%:+1.550 - TradingKey
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omeros Corp (OMER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - GlobeNewswire Inc.
OMER6080787 Bond Profile — Key Metrics - TradingView
Omeros repurchases $14.5M of 9.50% convertible notes, total retirements $30.5M - TradingView
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros CorporationOMER - PR Newswire
EMA Committee Rejects Marketing Authorization for Omeros Corp Antibody Narsoplimab - sekbernews.id
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return - Yahoo Finance
Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - AOL.com
Omeros shares drop 19% after EMA rejects narsop... - Pluang
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments - Seeking Alpha
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now? - Insider Monkey
Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026 - Minichart
Omeros to repurchase $16M of 9.50% notes, may buy up to $14.5M more - TradingView
Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt - Stock Titan
Omeros Corporation Reports First Quarter 2026 Financial Results - The National Law Review
Omeros stock drops 19% after EU rejects key dru... - Pluang
OMEROS CORP (OMER) Stock Chart - ChartMill
Omeros stock crashes on regulatory setback: Buy the dip? - MSN
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Sahm
Crude Oil Falls 4%; US Consumer Sentiment Rises In June - Sahm
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - AOL.com
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval - GuruFocus
Omeros stock crashes on regulatory setback: buy the dip? - Invezz
2.44%
0.02%
자본화:
|
볼륨(24시간):